150 related articles for article (PubMed ID: 34036848)
1. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States.
Herrera EM; Joseph C; Brouwer ES; Gandhi V; Czorniak M
COPD; 2021 Jun; 18(3):315-324. PubMed ID: 34036848
[TBL] [Abstract][Full Text] [Related]
2. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
[No Abstract] [Full Text] [Related]
4. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
5. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.
Karl FM; Holle R; Bals R; Greulich T; Jörres RA; Karch A; Koch A; Karrasch S; Leidl R; Schulz H; Vogelmeier C; Wacker ME;
Respir Res; 2017 Apr; 18(1):60. PubMed ID: 28416015
[TBL] [Abstract][Full Text] [Related]
6. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
8. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.
Campos MA; Alazemi S; Zhang G; Wanner A; Salathe M; Baier H; Sandhaus RA
Respir Med; 2009 Oct; 103(10):1532-9. PubMed ID: 19464158
[TBL] [Abstract][Full Text] [Related]
9. Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency.
Jarosch I; Hitzl W; Koczulla AR; Wencker M; Welte T; Gloeckl R; Janciauskiene S; Kenn K
Respir Med; 2017 Sep; 130():98-101. PubMed ID: 29206641
[TBL] [Abstract][Full Text] [Related]
10. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States.
Sieluk J; Levy J; Sandhaus RA; Silverman H; Holm KE; Mullins CD
Chronic Obstr Pulm Dis; 2018 Nov; 6(1):6-16. PubMed ID: 30775420
[No Abstract] [Full Text] [Related]
11. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.
Greulich T
COPD; 2017 Mar; 14(sup1):S8-S11. PubMed ID: 28306355
[TBL] [Abstract][Full Text] [Related]
12. One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States.
Blanchette CM; Zacherle E; Noone JM; Van Doren BA; Roy D; Howden R
J Health Econ Outcomes Res; 2017; 5(1):65-74. PubMed ID: 37664693
[No Abstract] [Full Text] [Related]
13. Labelling Alpha-1 antitrypsin deficiency in the medical record - A call to action.
Riley L; Lascano J
Respir Med; 2022 Mar; 193():106749. PubMed ID: 35124356
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study.
May D; Kponee-Shovein K; Mahendran M; Downes N; Sheng K; Lefebvre P; Cheng WY
BMC Neurol; 2023 Apr; 23(1):141. PubMed ID: 37016355
[TBL] [Abstract][Full Text] [Related]
15. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
[TBL] [Abstract][Full Text] [Related]
16. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory.
Belmonte I; Nuñez A; Barrecheguren M; Esquinas C; Pons M; López-Martínez RM; Ruiz G; Blanco-Grau A; Ferrer R; Genescà J; Miravitlles M; Rodríguez-Frías F
Int J Chron Obstruct Pulmon Dis; 2020; 15():2421-2431. PubMed ID: 33116457
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening.
Hiller AM; Piitulainen E; Tanash H
Int J Chron Obstruct Pulmon Dis; 2022; 17():43-52. PubMed ID: 35023912
[TBL] [Abstract][Full Text] [Related]
18. Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism.
Basil N; Ekström M; Piitulainen E; Lindberg A; Rönmark E; Jehpsson L; Tanash H
J Thromb Haemost; 2021 Jun; 19(6):1519-1525. PubMed ID: 33763945
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database.
Greulich T; Nell C; Hohmann D; Grebe M; Janciauskiene S; Koczulla AR; Vogelmeier CF
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 27824593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
